# A Trial Investigating the Effect of 4 Weeks Dosing of XEN-D0501 on Blood Glucose Reduction in Patients With Diabetes

> **NCT05353686** · PHASE2 · COMPLETED · sponsor: **Pila Pharma** · enrollment: 54 (actual)

## Conditions studied

- Efficacy
- Safety
- Pharmacokinetics
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Placebo
- **DRUG:** XEN-D0501

## Key facts

- **NCT ID:** NCT05353686
- **Lead sponsor:** Pila Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-25
- **Primary completion:** 2019-12-19
- **Final completion:** 2019-12-19
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2022-04-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05353686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05353686, "A Trial Investigating the Effect of 4 Weeks Dosing of XEN-D0501 on Blood Glucose Reduction in Patients With Diabetes". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05353686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*